https://endpts.com/sp/biotech-halftime-report-after-a-bumpy-year-is-biotech-ready-to-rebound/
Biopharma firms are flush with cash and with looming patent cliffs and depressed valuations among some smaller firms, we could see more deal activity through year-end. The possibility is further bolstered by management commentary, which continues to suggest openness to M&A deals. What’s changed is that large biopharma seems to be preferring smaller, earlier stage deals, private companies, or discounted late-stage assets, rather than the large $15 billion acquisitions we’ve seen in the past.
https://endpts.com/sp/biotech-halftime-report-after-a-bumpy-year-...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.4¢ |
Change
-0.002(2.63%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.6¢ | 7.4¢ | $34.74K | 462.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 82682 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 1991 | 1 |
View Market Depth
| Last trade - 14.07pm 19/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.4¢ |
Change
-0.002 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.5¢ | 7.5¢ | 7.4¢ | 40041 | ||
| Last updated 14.07pm 19/04/2024 ? | |||||
| PER (ASX) Chart |